Connect with us

Business insider

Schonfeld is raising money for its $2.2 billion fundamental equity fund. Here are the highlights of its 24-page pitch to investors laying out fees, performance, and personnel. | Markets Insider

Steven Schonfeld and his senior management continue to grow their team. Michael Nagle/Getty Schonfeld Strategic Advisors, the $5.8 billion hed……

Published

on

Michael Nagle/Getty

  • Schonfeld Strategic Advisors, the $5.8 billion hedge-fund manager founded by billionaire Steven Schonfeld, is raising money for its Fundamental Equity Fund.
  • Business Insider obtained a copy of the presentation the firm is sending to prospective investors.
  • The 24-page presentation outlines the firm’s focus and the fund’s selling points, including its qualifications of the 52 portfolio managers that contribute to the $2.2 billion fund and the fees it charges. 
  • Visit Business Insider’s homepage for more stories.
  • Schonfeld Strategic Advisors wants more money.

    The $5.8 billion hedge-fund manager is in the process of raising more capital for its $2.2 billion Fundamental Equity Fund, according to a presentation sent to prospective investors obtained by Business Insider.

    The presentation goes into detail on the make-up of both the fund — its expenses, structure, performance, and personnel — as well as the firm, which was founded by billionaire Steven Schonfeld and is currently run by CIO Ryan Tolkin and president Andrew Fishman. The firm declined to comment.

    The presentation is 24 pages, and dense with information.

    The firm breaks down the three different subsectors that its portfolio managers fall into — quant, fundamental equity, and tactical trading, which looks to take advantage of random market dislocations like index rebalancing — and where each of them fit in the firm’s two funds. 

    Schonfeld has $5.8 billion in outside capital, including hundreds of millions from its own portfolio managers, across its two funds, the Fundamental Equity fund and the larger Strategic Partners fund. While Schonfeld has been investing and operating in the markets for decades, the firm only recently decided to take outside capital, in 2016.

    In an interview with Business Insider in 2019, Tolkin, the firm’s CIO, said that the goal was to become the premier equity manager in the world.

    The firm’s diversified strategies help protect against one bad bet sinking the fund, but means the headcount on the investment team runs high.

    Schonfeld, with its dozens of portfolio managers, has nearly 200 analysts, traders, PMs, and researchers. In total, the firm has more than 800 people working at it. For comparison, at Tiger Global, which manages $42 billion across different funds, less than 40 people work in investment roles, according to the firm’s regulatory filing from March. 

    The firm touts its fundamental equity portfolio managers’ backgrounds in the presentation to prospective investors: The most common resume pit stops are at Steve Cohen’s former firm SAC Capital and current manager Point72 (12), Ken Griffin’s Citadel(10), Izzy Englander’s Millennium (8,) and the eponymous manager of Dmitry Balyasny (6), who used to work at Schonfeld. 

    See more: Inside the alumni network of billionaire Israel Englander, the founder of $46 billion hedge-fund behemoth Millennium

    The firm uses its existing portfolio managers and recruiters to get leads on new managers, and then the due diligence begins. The first stage of the process includes an independent assessment by each member of the firm’s advisory committee, a back-test of performance, and a risk questionnaire. 

    Then a candidate will be asked for references, to construct a budget for their team, and give a vision on future hires while laying out how they come up with investment ideas. Then senior management still has to debate whether a new hire is worth the investment and finalize the deal. 

    “Why Schonfeld?” one slide’s title reads.

    “Talent Is Our Strategy.” 

    Still, it has not met the performance goals the firm lists in the presentation, which is to be positive at least 75% of the months it trades in. So far in the 51 months of performance Schonfeld is revealing to investors, the fund has made money in 36 of them — a rate of 71%.

    The fund’s biggest sector exposure is to IT companies, with 18% of the fund’s portfolio invested in those companies, according to one slide in the presentation. Meanwhile, a majority of the fund’s exposure is to American companies with Asian companies in a distant second. The firm has offices in Singapore and Hong Kong, as well as London, and is spread across the US. Portfolio managers work from typical places like New York, Chicago, and Los Angeles, as well as Dallas, South Carolina, and Florida.

    Investors have three different fee and lock-up structures they can access if they want into the fund, and there are some advantages for making a big bet on Schonfeld.

    For those willing to put up a minimum of $25 million, Schonfeld’s Class A shares charge investors a 2% management fee and 20% performance fee, but has no withdrawal fees and can pull their capital out at any time.

    For the two latter classes, investors only need to put up $10 million, according to the presentation. 

    Source: https://markets.businessinsider.com/news/stocks/inside-schonfelds-pitch-for-its-22-billion-fundamental-equity-fund-2020-11-1029798552

    [ALT0]

    Continue Reading
    Click to comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Business insider

    Blackstone’s betting $6 billion on the rental market – here’s why private-equity loves real estate right now

    Jonathan Gray, Blackstone president and chief operating officer Heidi Gutman/NBCUniversal via Getty Images Blackstone is all-in on rent resets…

    Published

    on

    Jonathan GrayJonathan Gray, Blackstone president and chief operating officer

    Heidi Gutman/NBCUniversal via Getty Images

    • Blackstone is all-in on rent resets and long-term property assets to combat potential inflation.
    • Private equity firms have trillions of dollars in cash to put to work on acquisitions.
    • Blackstone’s share price ticked over $100 for the first time this month.
    • See more stories on Insider’s business page.

    It’s been quite the month for Blackstone.

    The private-equity behemoth is part of a consortium of investors that bought Medline for about $34 billion, its share price ticked over $100 for the first time, and it’s doubling down on residential real estate with a $6 billion Home Partners of America buy.

    It’s a bet on scorching demand for housing continuing, and also a defensive move as inflation worries start to seep into investors’ minds. The average price of a home topped $350,000 for the first time inn May, according to the National Association of Realtors, logging the largest-ever increase in prices since the NAR began tracking data.

    “Whether it’s apartments, storage facilities for warehouse distribution, or single-family homes, private-equity is getting into this as an inflation hedge,” Nicholas Tsafos, a partner with accounting firm EisnerAmper, told Insider.

    Home Partners, which owns more than 17,000 homes in the US, rents out these properties, but tenants have an opportunity to someday buy the home.

    In the single-family rental arena, private-equity firms can hike rents, while also holding onto profitable, tangible assets.

    “Because interest rates are low, and with the potential for a pick-up in inflation, private-equity also feels the need to be long on hard assets,” Tsafos said. “In real estate, you buy it today and then flip it for a higher price.”

    Jon Gray, Blackstone’s president and COO, alluded to it during the firm’s earnings call in April when he said multi-family apartments that come with the ability to reset rents were key for Blackstone.

    The firm bought many houses at remarkable discounts after the housing market crashed in 2007. It accumulated a number of single-family homes through a former portfolio company Invitation Homes. Blackstone sold its final block of shares in the company in 2019.

    The private-equity shop also favors logistics spaces, such as warehousing, life sciences offices, and media and studio businesses with offices, according to a June 22 research note from UBS.

    In October, Blackstone made a handsome investment when it sold life sciences real-estate company BioMed Realty for $14.6 billion, after acquiring it for about $8 billion in January 2016.

    And it’s not just Blackstone. Fellow private-equity investor KKR is investing in My Community Homes, a platform that buys and manages single-family rental properties, according to Bloomberg.

    KKR will invest in My Community Homes through its real-estate and private-credit vehicles.

    A spokesperson for KKR was not immediately available to comment.

    The Carlyle Group said in May that it provided up to $300 million to Four Springs Capital Trust, a private REIT that acquires and manages single-tenant properties with long-term net leases.

    Four Springs will use the money to build its portfolio, which encompasses 122 properties across 29 states, Carlyle said in a press release.

    The move on real estate comes while private investment firms sit on more than $1 trillion in cash. Borrowing costs, too, remain subdued as the Fed keeps interest rates at all-time lows.

    Given the sheer amount of dry powder available, coupled with accommodative credit markets, private-equity is keen to conduct a surfeit of acquisitions, and isn’t shy about injecting large sums of equity into prospective investments.

    Medline, for example, is expected to raise roughly $17 billion from the debt markets, while the private investors are providing a similar amount in equity.

    “Big leveraged buyouts are back in vogue,” said Christopher Zook, chairman and CIO of alternative investment manager CAZ Investments. “Whether it’s KKR or Blackstone, they have large capital to put to work. So they’ve got to do a ton of deals.”

    Disclaimer: KKR holds a majority stake in Insider’s parent company, Axel Springer.

    It’s been quite the month for Blackstone.

    Source: https://markets.businessinsider.com/news/stocks/blackstone-home-partners-america-single-family-rental-real-estate-inflation-2021-6-1030556791

    blackstone's-betting-$6-billion-on-the-rental-market---here's-why-private-equity-loves-real-estate-right-now

    Continue Reading

    Business insider

    Trading the Fed, plus insights from a 99th-percentile fund manager

    Hello and welcome to Insider Investing. I'm Joe Ciolli, and I'm here to guide you through the current market and investing landscape. Here…

    Published

    on

    Hello and welcome to Insider Investing. I’m Joe Ciolli, and I’m here to guide you through the current market and investing landscape. Here’s what’s on the docket:

    If you aren’t yet a subscriber to Insider Investing, you can sign up here.

    Have thoughts on the newsletter? Just want to talk markets? Feel free to drop me a line at [email protected] or on Twitter @JoeCiolli.

    Fed-driven portfolio adjustments GettyImages 1228670990

    Pool/Getty Images

    The Federal Reserve left interest rates steady this past week while setting the stage for two hikes by year-end 2023. Traders, who took a wait-and-see approach before the Fed meeting, quickly sprung into action. Insider spoke with Wall Street and crypto investors to gauge how to position for the hawkish shift.

    Read the full story here:

    The Fed has left rates steady while signaling 2 potential hikes by the end of 2023. Here is what to do with your stocks, bonds, and digital assets, according to top Wall Street and crypto investors.99th-percentile insights and stock picks Dave Ellison

    Hennessy Funds

    Financial-sector stocks have outperformed the rest of the market over the last several months. Hennessy Funds’ Dave Ellison – who’s in the 99th percentile compared to peers over the past year – told Insider he expects their strong performance to continue. He shared 5 financial stocks to buy now in order to take advantage of the remaining upside.

    Read the full stories here:

    Dave Ellison has beaten 99% of his peers over the last year managing the Hennessy Small-Cap Financial Fund. He breaks down why he thinks financial stocks still have room to run – and shares 5 names to bet onSPAC shorts SPACs and hedge funds 2x1

    Brian Snyder/Reuters; Michael Loccisano/Getty Images; Samantha Lee/Insider

    Short interest in SPACs stood at $3.2 billion in mid-June, up from $2.7 billion. The uptick in SPAC shorts comes as the market works to recover from a weeks-long slowdown, and one ETF manager expects recently “de-SPACed” companies to see short activity surge soon. Exclusive data shows the 20 most-shorted blank-check companies right now.

    Read the full stories here:

    Bets against SPACs are revving back up as the market attempts a comeback. Here are the 20 most-shorted blank-check companies now.YOU’RE INVITED: A Millennial Guide to Home Ownership

    Join us and learn how to navigate the complicated process of buying a home in today’s hot market on Tuesday, June 22 at 12 p.m. ET – during a free, hour-long virtual event presented by Fidelity.

    Register here.

    Stock pick central

    Seeking experts who are willing to name names? Look no further:

    Have thoughts on the newsletter? Just want to talk markets? Feel free to drop me a line at [email protected] or on Twitter @JoeCiolli.

    Source: https://markets.businessinsider.com/news/stocks/trading-fed-99th-percentile-picks-spac-short-selling-insider-investing-2021-6-1030537490

    trading-the-fed,-plus-insights-from-a-99th-percentile-fund-manager

    Continue Reading

    Business insider

    Artificial Organs Market | $ 10.90 billion growth expected during5 | Technavio

    NEW YORK, June 18, 2021 /PRNewswire/ — The artificial organs market is expected to grow by USD 10.90 billion during 2021-2025, according to Techn…

    Published

    on

    NEW YORK, June 18, 2021 /PRNewswire/ — The artificial organs market is expected to grow by USD 10.90 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 pandemic on the artificial organs market in optimistic, probable, and pessimistic forecast scenarios.

    Technavio has announced its latest market research report titled Artificial Organs Market by Product and Geography - Forecast and Analysis 2021-2025

    Understand the in-depth market insights with value chain analysis and validation techniques:
    Download FREE Sample Report

    With the continuing spread of the novel coronavirus pandemic, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through response, recovery, and renew phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis towards the Next Normal.

    The artificial organs market will witness a positive impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio’s pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.

    This post-pandemic business planning research will aid clients to:

    • Adjust their strategic planning to move ahead once business stability kicks in.
    • Build Resilience by making effective resource and investment choices for individual business units, products, and service lines.
    • Conceptualize scenario-based planning to mitigate future crisis situations.

    Key Considerations for Market Forecast:

    • Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
    • Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
    • Pre- as well as post-COVID-19 market estimates
    • Quarterly impact analysis and updates on market estimates

    Major Three Artificial Organs Market Participants:

    Abbott Laboratories
    Abbott Laboratories offers ASSURITY MRI PACEMAKER. Its size and shape allow surgeons to make small incisions during the implantation procedure. This pacemaker requires a small pocket under the skin of the chest during implantation.

    Asahi Kasei Corp.
    Asahi Kasei Corp. offers REXEED. It is a hemodialyzer for effective removal of toxins and low molecular weight proteins.

    B. Braun Melsungen AG
    B. Braun Melsungen AG offers Diacap Pro. It is a hemodialyzer that removes wastes and excess fluid from the blood.

    If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Get report snapshot here to get detailed market share analysis of market participants during COVID-19 lockdown:
    https://www.technavio.com/report/artificial-organs-market-industry-analysis

    Artificial Organs Market 2021-2025: Segmentation

    Artificial organs market is segmented as below:

    • Product
      • Artificial Heart
      • Artificial Kidney
      • Cochlear Implants
      • Artificial Pancreas
    • Geography
      • North America
      • Europe
      • Asia
      • ROW

    The artificial organs market is driven by the increasing prevalence of chronic disorders. In addition, the growing demand for pacemakers and dialyzers is expected to trigger the artificial organs market toward witnessing a CAGR of almost 9% during the forecast period.

    Know more information on factors assisting the artificial organs market growth during the next five years, Request Free Sample Report @
    https://www.technavio.com/talk-to-us?report=IRTNTR44011

    Related Report on Healthcare Include:

    Global Breast Reconstruction Market- The breast reconstruction market is segmented by product (breast implants and tissue expanders) and geography (North America, Europe, Asia, and ROW).
    Download FREE Sample Report

    Global Dental Infection Control Products Market- The dental infection control products market is segmented by product (consumables and equipment) and geography (North America, Europe, Asia, and ROW).
    Download FREE Sample Report

    Market Drivers

    Market Challenges

    Market Trends

    Vendor Landscape

    • Vendors covered
    • Vendor classification
    • Market positioning of vendors
    • Competitive scenario

    About Us
    Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

    Contact
    Technavio Research
    Jesse Maida
    Media & Marketing Executive
    US: +1 844 364 1100
    UK: +44 203 893 3200
    Email: [email protected]
    Website: www.technavio.com/
    Report Page: https://www.technavio.com/report/artificial-organs-market-industry-analysis

    Technavio (PRNewsfoto/Technavio)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/artificial-organs-market—10-90-billion-growth-expected-during-2021-2025–technavio-301315548.html

    SOURCE Technavio

    Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.

    With the continuing spread of the novel coronavirus pandemic, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through response, recovery, and renew phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis towards the Next Normal.

    Source: https://markets.businessinsider.com/news/stocks/artificial-organs-market-10-90-billion-growth-expected-during-2021-2025-technavio-1030536439

    artificial-organs-market-|-$-10.90-billion-growth-expected-during5-|-technavio

    Continue Reading

    Title

    Ventureburn5 hours ago

    ZwartTech launches Talent Foundation to equip Africans with digital skills

    Lagos-based ZwartTech has announced the launch of its new edtech, Zwart Talent Foundation (ZTF) in a statement on 30 July...

    CNBC1 day ago

    Earnings

    Corporate Company Earnings, Find Earnings Per Share and Earnings History Online

    Bioengineer3 days ago

    Reduced microbial stability linked to soil carbon loss in active layer under alpine permafrost degra

    Credit: NIEER Chinese researchers have recently discovered links between reduction in microbial stability and soil carbon loss in the active

    Reuters4 days ago

    Chipmaker TSMC says too early to say on Germany expansion

    Taiwan Semiconductor Manufacturing Co Ltd (TSMC) (2330.TW) said on Monday that it was too early to say whether it will...

    Bioengineer5 days ago

    SNMMI Image of the Year: PET imaging measures cognitive impairment in COVID-19 patients

    Credit: G Blazhenets et al., Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of

    Techcrunch6 days ago

    The DL on CockroachDB – TechCrunch

    As college students at Berkeley, Spencer Kimball and Peter Mattis created a successful open-source graphics program, GIMP, which got the...

    CNBC6 days ago

    International: Top News And Analysis

    CNBC International is the world leader for news on business, technology, China, trade, oil prices, the Middle East and markets.

    Blockchain news1 week ago

    Ethereum is Expected to Undergo a 90% Daily Emission Reduction Following ETH 2.0 Upgrade

    Market analyst Lark Davis believes that Ethereum 2.0 upgrade will prompt a 90% daily emission reduction from 12,800 to 1,280.

    Reuters1 week ago

    EXCLUSIVE India watchdog accuses Amazon of concealing facts in deal for Future Group unit

    India's antitrust regulator has accused Amazon.com Inc (AMZN.O) of concealing facts and making false submissions when it sought approval for...

    Bioengineer1 week ago

    Scientists demonstrate promising new approach for treating cystic fibrosis

    Scientists led by UNC School of Medicine researchers Silvia Kreda, Ph.D., and Rudolph Juliano, Ph.D., created an improved oligonucleotide therapy

    Review

      Select language

      Trending